HCG

Monograph № 009

A molecule that speaks the language the testes already understand, preserving the hormonal conversation that exogenous testosterone would simply replace.

Sequence

237 aa + 145 aa subunits

Half-life

~36 hours (terminal)

Route

Subcutaneous · Intramuscular

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

Organon / Pregnyl

First pharmaceutical isolation

First disclosed

1927

Ascheim & Zondek pregnancy assay

Regulatory status

FDA-Approved

Hypogonadism · Cryptorchidism · ART

Studied for

Testosterone Preservation · Fertility · Leydig Cell Function

Endogenous steroidogenesis support

Mechanism

How HCG keeps testosterone being made

HCG does not introduce testosterone. It speaks the language the testes already understand – mimicking the luteinizing hormone pulse that instructs Leydig cells to synthesize androgens from cholesterol. The distinction matters. Where exogenous testosterone replaces a signal, HCG preserves the conversation.

LH receptor binding activates adenylyl cyclase via Gs coupling, elevating intracellular cAMP and upregulating StAR protein expression. Cholesterol transport into the mitochondrial matrix is the rate-limiting step in androgen synthesis.

Leydig cell steroidogenesis proceeds sequentially through CYP11A1, CYP17A1, 3β-HSD, and 17β-HSD to produce testosterone. HCG sustains this entire enzymatic cascade during periods of HPG axis suppression.

Spermatogenesis depends on intratesticular testosterone concentrations 50 to 100 times higher than serum levels, a gradient only sustained LHR activation can maintain. Sertoli cell paracrine support proceeds in parallel and requires the same gonadal stimulus.

HCG acts downstream of the pituitary and does not restore hypothalamic GnRH pulsatility. It is a gonadal bridge, not a tool for axis rehabilitation.

What we observe

What people saw in fertility and testes

The outcomes below reflect patterns reported across clinical trials, observational cohorts, and endocrinological reviews. They describe what investigators have noted under studied conditions, not what any individual should expect. Aeterna does not prescribe, dispense, or sell; this summary exists to illuminate the evidence.

Intratesticular Testosterone Maintenance

Studies in men receiving exogenous testosterone report that co-administration of HCG at low doses (125–500 IU every other day) substantially preserves intratesticular testosterone concentrations compared to testosterone monotherapy, which suppresses endogenous LH to near-undetectable levels.

Observed in controlled clinical studies; magnitude varies with dose and individual LH sensitivity.

Testicular Volume Preservation

Testicular atrophy is a well-documented consequence of prolonged exogenous androgen use. The literature reports that concurrent HCG administration attenuates this reduction, with some cohorts demonstrating near-complete preservation of baseline testicular dimensions over 12-week observation periods.

Observational and controlled data; individual variation is considerable.

Spermatogenesis Support

In hypogonadotropic hypogonadism, HCG monotherapy or combination with FSH has been shown to initiate or restore spermatogenesis in a meaningful proportion of subjects. The literature reports sperm in ejaculate in approximately 75–90% of men with secondary hypogonadism treated with gonadotropin therapy over 12–24 months.

Data from fertility literature; outcomes depend heavily on etiology and baseline testicular function.

Serum Testosterone Elevation

In men with intact Leydig cell function, HCG administration produces dose-dependent increases in serum testosterone. Doses of 1,500–5,000 IU administered two to three times weekly have been associated with testosterone elevations into or above the physiological range, depending on baseline gonadal reserve.

Well-established pharmacodynamic effect; clinical utility depends on indication and axis status.

Cryptorchidism - Partial Response

In prepubertal males with undescended testes, HCG has been used to stimulate androgen-dependent gubernacular descent. Response rates in the literature range from 15–55%, with bilateral cases and those with testes palpable in the inguinal canal showing the most favorable outcomes. Surgical correction remains the standard of care when hormonal therapy is insufficient.

Established pediatric indication; response rates vary substantially by anatomy and age.

Luteal Phase Support in ART

In assisted reproductive technology protocols, HCG serves as the ovulation trigger – replacing the endogenous LH surge – and supports corpus luteum function in the luteal phase. The literature documents reliable oocyte maturation and luteinization when HCG is administered 34–36 hours prior to oocyte retrieval.

Standard-of-care application in reproductive medicine; well-supported by decades of clinical data.

Evidence

What the studies found

Three studies are presented here as representative entries in a larger literature spanning reproductive endocrinology, andrology, and sports medicine. Each is cited with its primary finding and a representative statistic. Readers are encouraged to consult primary sources directly.

Journal of Clinical Endocrinology & Metabolism

2005

Intratesticular Testosterone Concentrations in Men Receiving Testosterone Replacement with and without HCG Co-administration

Randomized controlled study in eugonadal men receiving exogenous testosterone enanthate with or without adjunctive HCG (125 IU every other day). The HCG group maintained intratesticular testosterone concentrations within 25% of baseline, while the testosterone-only group experienced a decline exceeding 90% from baseline values. Serum testosterone was comparable between groups, underscoring that serum measurements do not reflect intratesticular milieu.

94%

decline in intratesticular testosterone in testosterone-only arm vs. near-preservation in HCG co-administration arm

Fertility and Sterility

2013

Gonadotropin Therapy for Induction of Spermatogenesis in Men with Hypogonadotropic Hypogonadism: A Systematic Review

Systematic review of 30 studies encompassing 1,042 men with hypogonadotropic hypogonadism treated with HCG alone or in combination with FSH. Spermatogenesis was achieved in 76% of subjects overall; combination therapy with FSH produced higher sperm concentrations and shorter time to first sperm appearance. Prior testosterone therapy did not significantly impair response when gonadotropin treatment was initiated.

76%

of men with hypogonadotropic hypogonadism achieved spermatogenesis with gonadotropin therapy

Andrology

2019

Low-Dose HCG Preserves Testicular Volume and Sperm Parameters During Testosterone Replacement Therapy: A Prospective Cohort Study

Prospective 24-week cohort study in 68 hypogonadal men initiating testosterone replacement therapy. Subjects receiving adjunctive HCG (250 IU three times weekly) demonstrated preservation of mean testicular volume within 8% of baseline, compared to a 21% reduction in the testosterone-only cohort. Sperm concentration remained detectable in 89% of the HCG group versus 34% of controls at week 24.

89%

of HCG co-administration subjects retained detectable sperm concentration at 24 weeks, versus 34% in controls

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

5000 IU lyophilized powder

Diluent

2.0 mL bacteriostatic water

Final concentration

2,500 IU/mL

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 500 IU subcutaneous, 3× weekly (Mon/Wed/Fri) for testicular maintenance during TRT).

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Weeks 1–12

500 IU

Once daily · 20 units (0.20 mL)

Standard

500 IU

2-3x weekly · SC

Fertility protocol

1500-3000 IU

3x weekly · Higher dose

On-cycle TRT support

500 IU

twice weekly

Most common adjunct

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F).
After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 60 days.
Do not freeze reconstituted solution; freezing degrades the glycoprotein structure and reduces biological activity.
Allow refrigerated solution to reach room temperature for 5–10 minutes before injection to reduce injection discomfort.
Inspect reconstituted solution for particulate matter or discoloration before each use; discard if either is present.

Side effects

What members describe

Injection site reactions - erythema, mild swelling, and transient discomfort are the most commonly reported local effects.
Gynecomastia - HCG stimulates testicular aromatase activity, increasing conversion of testosterone to estradiol; estrogen-sensitive individuals may require monitoring and adjunctive aromatase inhibitor consideration.
Ovarian Hyperstimulation Syndrome (OHSS) - in female ART protocols, HCG trigger carries a risk of OHSS ranging from mild to severe; risk stratification and luteal phase management are standard practice.
Headache, fatigue, and mood variability have been reported, particularly at higher doses; these effects are generally transient and dose-dependent.
Fluid retention and edema may occur secondary to elevated estradiol; monitoring of electrolytes and blood pressure is prudent in longer protocols.

Contradictions

Reasons to abstain

Known or suspected androgen-sensitive malignancy (prostate carcinoma, testicular carcinoma) - HCG stimulates endogenous testosterone production and is contraindicated in these settings.
Precocious puberty - HCG administration in children with premature activation of the HPG axis may accelerate bone age advancement and compromise adult stature.
Primary hypogonadism (hypergonadotropic) - absent or severely diminished Leydig cell reserve renders HCG ineffective; the signal cannot be received where the receptor apparatus is absent.
Uncontrolled thyroid or adrenal dysfunction - steroidogenic pathways share substrate and cofactor pools; systemic endocrine instability should be addressed before gonadotropin therapy is initiated.
Hypersensitivity to HCG or any excipient in the formulation - anaphylactic reactions, though rare, have been reported; prior allergic response to gonadotropin preparations is a contraindication.

Synergies

What to pair with HCG

HCG rarely operates in isolation within clinical protocols. Its role as a downstream LH signal makes it a natural complement to agents that act at the hypothalamic or pituitary level, or to exogenous androgens that suppress the axis it is meant to sustain. The pairings below reflect patterns in the clinical and research literature – not protocol recommendations.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Testosterone (Exogenous)

The most studied pairing in the andrology literature. Exogenous testosterone suppresses endogenous LH; HCG replaces that signal downstream, preserving intratesticular testosterone, testicular volume, and spermatogenic potential that testosterone monotherapy consistently erodes.

Hormonal

Clomiphene Citrate (Clomid)

Clomiphene acts at the hypothalamic level, blocking estrogen negative feedback to increase endogenous LH and FSH secretion. When used sequentially after HCG – or in combination in certain fertility protocols – the two agents address different nodes of the HPG axis, offering a more complete approach to axis rehabilitation than either provides alone.

Hormonal – Axis Restoration

Recombinant FSH (rFSH)

HCG provides the LH signal; FSH provides the Sertoli cell signal. In hypogonadotropic hypogonadism, both are absent. The literature consistently reports that combination HCG plus rFSH produces superior spermatogenesis outcomes compared to HCG monotherapy, particularly in men with no prior pubertal development.

Reproductive Endocrinology

Anastrozole

HCG-stimulated Leydig cells upregulate aromatase activity, increasing the conversion of testosterone to estradiol. In individuals prone to estrogen-mediated side effects – gynecomastia, fluid retention, mood variability – low-dose aromatase inhibition is sometimes employed as an adjunct. The literature supports this approach cautiously; over-suppression of estradiol carries its own adverse profile.

Hormonal – Estrogen Management

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

Is HCG the same as testosterone?

No. HCG does not contain testosterone and does not directly introduce androgens into the body. It stimulates the Leydig cells of the testes to produce testosterone endogenously – a meaningful distinction. The signal and the hormone it produces are separate entities, with different pharmacokinetics, receptor profiles, and regulatory statuses.

Why is HCG used alongside testosterone replacement therapy?

Exogenous testosterone suppresses the hypothalamic-pituitary axis, reducing LH to near-undetectable levels. Without LH stimulation, Leydig cells become quiescent, intratesticular testosterone falls dramatically, and testicular volume declines. HCG replaces the absent LH signal, maintaining Leydig cell activity and preserving the testicular environment – including spermatogenesis – that testosterone monotherapy would otherwise compromise.

Does HCG restore the HPG axis?

Not in the conventional sense. HCG acts downstream of the pituitary, bypassing rather than rehabilitating the hypothalamic-pituitary axis. It sustains testicular function without restoring the endogenous signaling cascade. Agents that act at the hypothalamic level – such as clomiphene or GnRH analogues – are used when axis restoration, rather than downstream stimulation, is the clinical objective.

Can HCG cause estrogen-related side effects?

Yes. By stimulating testosterone production, HCG also increases substrate available for aromatization. Leydig cells themselves express aromatase, and HCG upregulates this activity. Elevated estradiol can produce gynecomastia, fluid retention, and mood changes in susceptible individuals. Monitoring estradiol during HCG protocols is standard practice in the clinical literature.

What distinguishes HCG from recombinant LH (rLH)?

Both bind the LH receptor, but HCG has a substantially longer half-life – approximately 36 hours versus 60 minutes for endogenous LH – due to its additional sialic acid residues on the beta subunit. This extended receptor occupancy produces a more sustained steroidogenic stimulus, which is pharmacologically useful but also means that the signal is less pulsatile than physiological LH. Whether tonic versus pulsatile LH stimulation has meaningful long-term consequences for Leydig cell health remains an open question in the literature.

Is HCG detectable in anti-doping testing?

Yes. HCG is prohibited in male athletes by the World Anti-Doping Agency (WADA) at all times, both in and out of competition. It is detectable in urine via immunoassay and confirmatory mass spectrometry. The prohibition reflects its capacity to stimulate endogenous testosterone production, which would otherwise be indistinguishable from natural testosterone in standard T/E ratio testing. This is a regulatory and ethical matter; the pharmacology is neutral on the question.

In the same family